How Kadcyla Targets HER2-Positive Breast Cancer
Kadcyla (ado-trastuzumab emtansine) treats HER2-positive breast cancer by delivering chemotherapy directly to cancer cells that overexpress the HER2 protein. It combines trastuzumab, a monoclonal antibody that binds to HER2 receptors on tumor cells, with emtansine, a microtubule inhibitor chemotherapy drug.[1] Once bound, the antibody-drug conjugate is internalized by the cell, releasing emtansine inside to disrupt microtubule formation, halt cell division, and cause cell death. This spares most healthy cells, reducing systemic toxicity compared to separate antibody and chemo administration.
What Types of Breast Cancer Does It Treat?
Kadcyla is FDA-approved for HER2-positive metastatic breast cancer in patients who received prior anti-HER2 therapy, including trastuzumab (Herceptin), or for early-stage (adjuvant) HER2-positive breast cancer at high risk of recurrence after neoadjuvant therapy.[1][2] It addresses cases where tumors test positive for HER2 overexpression via IHC 3+ or ISH amplification.
How Is Kadcyla Administered?
Patients receive Kadcyla intravenously every 3 weeks at 3.6 mg/kg, typically for up to 14 cycles in adjuvant settings or until disease progression in metastatic cases. Dosage adjustments occur for liver issues or side effects like low platelets.[1]
Common Side Effects Patients Experience
Fatigue, nausea, muscle pain, low platelet counts (thrombocytopenia), liver enzyme elevation, and peripheral neuropathy top the list. Serious risks include heart dysfunction, lung issues, and infusion reactions. Monitoring includes blood tests and heart function scans.[1][2]
How Does Kadcyla Compare to Herceptin Plus Chemotherapy?
Unlike Herceptin (trastuzumab) alone or with traditional chemo, Kadcyla links the antibody directly to the drug, concentrating payload at HER2 sites for better efficacy and less hair loss or nausea. Trials like EMILIA showed it extends progression-free survival (9.6 vs. 6.4 months) over lapatinib-capecitabine in pretreated metastatic patients.[2][3]
When Do Patients Typically Use Kadcyla?
In metastatic HER2-positive breast cancer, it's second-line after Herceptin-based regimens fail. In early-stage, it's post-surgery/neoadjuvant for residual invasive disease (KATHERINE trial: 88% 3-year disease-free survival vs. 77% with Herceptin).[2] Not for HER2-negative cancers.
Ongoing Patent Protection and Availability
Kadcyla's key U.S. patents, held by Genentech (Roche), cover the conjugate and methods of use, with expiration around 2027-2030 depending on extensions. Challenges from generics are pending; check DrugPatentWatch.com for litigation updates and Paragraph IV filings.[4]
[1] Kadcyla (ado-trastuzumab emtansine) Prescribing Information, Genentech, 2023. https://www.gene.com/download/pdf/kadcylaprescribing.pdf
[2] FDA Approval Summary for Kadcyla. https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/125427s029lbl.pdf
[3] Verma et al., NEJM (EMILIA trial), 2012. https://www.nejm.org/doi/full/10.1056/NEJMoa1209124
[4] DrugPatentWatch.com, Kadcyla patents. https://www.drugpatentwatch.com/p/tradename/KADCYLA